Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Ann Clin Microbiol Antimicrob ; 22(1): 55, 2023 Jul 05.
Artigo em Inglês | MEDLINE | ID: mdl-37408075

RESUMO

Infections in critically-ill patients caused by extensively-drug-resistant (XDR)-Pseudomonas aeruginosa are challenging to manage due to paucity of effective treatment options. Cefepime/zidebactam, which is currently in global Phase 3 clinical development (Clinical Trials Identifier: NCT04979806, registered on July 28, 2021) is a novel mechanism of action based ß-lactam/ ß-lactam-enhancer combination with a promising activity against a broad-range of Gram-negative pathogens including XDR P. aeruginosa. We present a case report of an intra-abdominal infection-induced sepsis patient infected with XDR P. aeruginosa and successfully treated with cefepime/zidebactam under compassionate use. The 50 year old female patient with past-history of bariatric surgery and recent elective abdominoplasty and liposuction developed secondary pneumonia and failed a prolonged course of polymyxins. The organism repeatedly isolated from the patient was a New-Delhi metallo ß-lactamase-producing XDR P. aeruginosa resistant to ceftazidime/avibactam, imipenem/relebactam and ceftolozane/tazobactam, susceptible only to cefepime/zidebactam. As polymyxins failed to rescue the patient, cefepime/zidebactam was administered under compassionate grounds leading to discharge of patient in stable condition. The present case highlights the prevailing precarious scenario of antimicrobial resistance and the need for novel antibiotics to tackle infections caused by XDR phenotype pathogens.


Assuntos
Infecções Intra-Abdominais , Infecções por Pseudomonas , Sepse , Humanos , Cefepima/uso terapêutico , Cefepima/farmacologia , Infecções por Pseudomonas/tratamento farmacológico , Ensaios de Uso Compassivo , Cefalosporinas/uso terapêutico , Cefalosporinas/farmacologia , Antibacterianos/uso terapêutico , Antibacterianos/farmacologia , Monobactamas/farmacologia , Pseudomonas aeruginosa , beta-Lactamases/genética , Sepse/tratamento farmacológico , Infecções Intra-Abdominais/tratamento farmacológico , Polimixinas , Testes de Sensibilidade Microbiana
2.
Lung India ; 36(Supplement): S37-S89, 2019 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-32445309

RESUMO

Flexible bronchoscopy (FB) is commonly performed by respiratory physicians for diagnostic as well as therapeutic purposes. However, bronchoscopy practices vary widely across India and worldwide. The three major respiratory organizations of the country supported a national-level expert group that formulated a comprehensive guideline document for FB based on a detailed appraisal of available evidence. These guidelines are an attempt to provide the bronchoscopist with the most scientifically sound as well as practical approach of bronchoscopy. It involved framing appropriate questions, review and critical appraisal of the relevant literature and reaching a recommendation by the expert groups. The guidelines cover major areas in basic bronchoscopy including (but not limited to), indications for procedure, patient preparation, various sampling procedures, bronchoscopy in the ICU setting, equipment care, and training issues. The target audience is respiratory physicians working in India and well as other parts of the world. It is hoped that this document would serve as a complete reference guide for all pulmonary physicians performing or desiring to learn the technique of flexible bronchoscopy.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA